Wnt Signaling Pathway and Chronic Myelogenous Leukemia
As a type of cancer that starts in certain blood-forming cells of the bone marrow, chronic myeloid leukemia (CML) is caused by the formation of an abnormal gene called BCR-ABL1. The targeted medicine TKI for BCR-ABL1 has great effect on treating CML: however, TKI is not able to completely remove the...
Main Authors: | HOU Yan, LI Wenqian, FENG Jianming, AI Guo, XIE Youbang, HUA Qingcuo, ZHAO Changming |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-02-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0899.htm |
Similar Items
-
Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
by: Rita Ahmad, et al.
Published: (2021-04-01) -
Targeting the Process of c-MYC Stabilization in Chronic Myelogenous Leukemia
by: Sunohara, Maxwell
Published: (2017) -
Bilineage T-lymphoblastic/myeloid extramedullary blast crisis in chronic myelogenous leukemia
by: Indu M Nair, et al.
Published: (2016-01-01) -
Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
by: David N. Perdigoto, et al.
Published: (2017-10-01) -
TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01)